Know Cancer

or
forgot password

Prospective Evaluation of Plasma EBV DNA Half-life and PET-CT Scanning as a New Tool in Assessing Early Response to Chemotherapy in Patients With Advanced Nasopharyngeal Carcinoma


N/A
18 Years
N/A
Open (Enrolling)
Both
Advanced Nasopharyngeal Carcinoma

Thank you

Trial Information

Prospective Evaluation of Plasma EBV DNA Half-life and PET-CT Scanning as a New Tool in Assessing Early Response to Chemotherapy in Patients With Advanced Nasopharyngeal Carcinoma


Inclusion Criteria:



- undergo chemotherapy for any one of the following settings:

1. Setting 1: Neoadjuvant chemotherapy prior to cheom-RT

2. Setting 2: Palliative chemotherapy in Chemonaive patients

3. Setting 3: Palliative chemotherapy in previously treated patients (i.e. 2nd
line or 3rd line chemo)

- Age >= 18 years

- (ECOG) performance status of 0-2

- have detectable levels of pEBV DNA at baseline

- have measurable tumor sites by RECIST criteria

- have adequate bone marrow, renal and hepatic functions

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

To determine if measuring tumor metabolic response during chemotherapy can predict survival

Outcome Time Frame:

3 years

Safety Issue:

No

Principal Investigator

Brigette Ma, MD, FRCP

Investigator Role:

Principal Investigator

Investigator Affiliation:

Chinese University of Hong Kong

Authority:

Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee

Study ID:

NPC023

NCT ID:

NCT01365208

Start Date:

July 2011

Completion Date:

May 2014

Related Keywords:

  • Advanced Nasopharyngeal Carcinoma
  • Carcinoma
  • Nasopharyngeal Neoplasms

Name

Location